Lexmet-G2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby enhancing glycemic control. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and increasing peripheral glucose uptake. The synergistic action of these agents effectively lowers blood glucose levels in patients inadequately controlled by diet and exercise alone. Lexmet-G2 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including diet modification and physical activity. The prolonged-release formulation ensures a sustained therapeutic effect, minimizing fluctuations in plasma glucose and reducing the risk of hypoglycemia. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, primarily attributed to metformin. Rarely, hypoglycemia may occur due to glimepiride. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is recommended. Lexmet-G2 should be used under medical supervision, with dose adjustments based on glycemic response and tolerability to optimize diabetes control and reduce the risk of long-term complications.